# A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

> **NCT07219420** · PHASE3 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 300 (estimated)

## Conditions studied

- Palmoplantar Pustulosis

## Interventions

- **DRUG:** Bimekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07219420
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2027-12-27
- **Final completion:** 2029-11-22
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07219420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07219420, "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07219420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*